<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835938</url>
  </required_header>
  <id_info>
    <org_study_id>5189</org_study_id>
    <nct_id>NCT01835938</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of Erlotinib as an HCV Entry Inhibitor</brief_title>
  <official_title>Dose Finding and Early Efficacy Study of Erlotinib in Treatment of Chronic Hepatitis C Virus infection_proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Hepatitis C Virus (HCV) infection is a major cause of liver cirrhosis and
      hepatocellular carcinoma world-wide. Current combination therapy of pegylated
      interferon-alfa, ribavirin and protease inhibitors is limited by resistance and substantial
      side effects.

      The investigators identified epidermal growth factor receptor (EGFR) as host factor for HCV
      infection. Inhibition of kinase function of EGFR by approved inhibitor Erlotinib (TarcevaTM)
      broadly inhibits HCV infection of all major genotypes including viral escape variants
      resistant to host immune responses.

      Completed preclinical proof-of-concept studies in HCV cell culture and animal model systems
      demonstrate that inhibition of EGFR function by Erlotinib constitutes a novel antiviral
      approach for prevention and treatment of HCV infection (European patent application EP 08 305
      604.4, Filing date: September 26, 2008; Inserm, Paris, France and Lupberger et al. Nature
      Medicine 2011).

      Since Erlotinib (TarcevaTM) is an established approved drug for cancer treatment and has a
      well characterized safety profile in humans, the aim of the study is to investigate the
      safety, efficacy and pharmacokinetics of Erlotinib, a first-in-class entry inhibitor, for
      treatment of HCV infection in a randomized placebo-controlled double blind clinical trial in
      patients chronically infected with HCV. Following completion, this trial will set the stage
      for a further investigation of entry inhibitors as antivirals in combination with standard of
      care or direct antivirals such as HCV protease inhibitors. Thus, this randomized clinical
      trial will be an important step in the development of novel urgently needed antiviral
      therapies overcoming resistance.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of virologic response and short-term safety of Erlotinib in patients infected with HCV genotype 1b</measure>
    <time_frame>14-day assessment study</time_frame>
    <description>Determination of the recommended dose on the end point of dise-limiting toxicity (DLT), establishment of the maximum-tolerated dose (MTD), and response rate defined as a reduction of at least 1 log10 HCV RNA Levels after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetics of Erlotinib in HCV-infected patients</measure>
    <time_frame>14-day assessment study</time_frame>
    <description>- Evaluate the pharmacokinetics (AUC, Cmax) of Erlotinib.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of Erlotinib in HCV-infected patients and evaluation of drug resistance</measure>
    <time_frame>14-day assessment study</time_frame>
    <description>Analyzing the variability of viral species during treatment and evaluate potential resistance to Erlotinib</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <condition>HCV Genotype 1b</condition>
  <arm_group>
    <arm_group_label>1- Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib is a first class HCV entry inhibitor. In this study, Erlotinib will be administered in escalating doses in sequential patient cohorts for 14 days as follows:
Dose level (DL) 1 = 50 mg / day,
Dose level (DL) 2 = 100 mg / day, and
Dose level (DL) 3 = 150 mg / day .
Each Dose Level (DL) includes 4 patients (3 patients treated with Erlotinib and one patient treated with the Placebo). Dose escalation will proceed to the subsequent DL in the absence of DLT (dose-limiting toxicity) in 2 patients receiving Erlotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1- Erlotinib</intervention_name>
    <description>Erlotinib 50 mg tablet by mouth every day for 14 days,
Erlotinib 100 mg tablet by mouth every day for 14 days,
Erlotinib 150 mg tablet by mouth every day for 14 days,</description>
    <arm_group_label>1- Erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo 50 mg tablet by mouth every day for 14 days,
Placebo 100 mg tablet by mouth every day for 14 days,
Placebo 150 mg tablet by mouth every day for 14 days,</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic genotype 1b hepatitis C infection with detectable HCV RNA (&gt; 1x104 UI/mL)

          -  Naïve, relapser or non-responder to interferon with or without ribavirin

          -  Weight &gt; 45kg, BMI between 18 and 25 Kg/m2 who had a liver biopsy or liver FibroScan
             eliminating the presence of cirrhosis in the year before enrollment,

          -  Non-smoker or occasional smoker ( ie &lt; 3 cig/day)

        Exclusion Criteria:

          -  HIV or HBV infection

          -  Cirrhosis or Liver decompensation

          -  Chronic liver disease non related to HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Samira Fafi-Kremer, Pharma D, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratoire de Virologie PTM- Nouvel Hôpital CivilHôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Catherine Mutter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre d'investigation Clinique -P1002Nouvel Hôpital CivilHôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr François Habersetzer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Service d'Hépato-Gastro-Entérologie - Nouvel Hôpital CivilHôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Thomas BAUMERT, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Service d'Hépatogastroentérologie, NHC1, place de l'hôpital - BP n°42667091 STRASBOURG CEDEX</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pr. Michel Doffoel, MD, PhD</last_name>
    <phone>03 69 55 04 82</phone>
    <email>michel.doffoel@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pr. Thomas BAUMERT, MD, PhD</last_name>
    <phone>03 68 85 37</phone>
    <email>thomas.baumert@unistra.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie, NHC1, place de l'hôpital</name>
      <address>
        <city>Strasbourg Cedex</city>
        <state>Alsace</state>
        <zip>BP n°426</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pr. Michel DOFFOEL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2013</study_first_submitted>
  <study_first_submitted_qc>April 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <last_update_submitted>June 14, 2014</last_update_submitted>
  <last_update_submitted_qc>June 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus infection</keyword>
  <keyword>entry inhibitor</keyword>
  <keyword>kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

